Bridgefront Capital, LLC Atara Biotherapeutics, Inc. Transaction History
Bridgefront Capital, LLC
- $236 Million
- Q2 2024
Shares
2 transactions
Others Institutions Holding ATRA
# of Institutions
10Shares Held
3.07MCall Options Held
0Put Options Held
0-
Kpcb Xv Associates, LLC1.88MShares$15.2 Million19.79% of portfolio
-
Antipodean Advisors LLC New York, NY1MShares$8.09 Million8.12% of portfolio
-
Boxer Capital, LLC San Diego, CA166KShares$1.34 Million0.08% of portfolio
-
Lake Street Advisors Group, LLC11KShares$88,9900.0% of portfolio
-
American Portfolios Advisors Holbrook, NY4.5KShares$36,4050.0% of portfolio
About Atara Biotherapeutics, Inc.
- Ticker ATRA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,362,304
- Market Cap $763M
- Description
- Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferat...